Loading
companiesCompany
Heron Therapeutics
Heron Therapeutics makes long-acting supportive-care injectables: the antiemetics Sustol (extended-release granisetron) and Cinvanti (aprepitant emulsion), plus the post-surgical analgesic Zynrelef.
Overview
Heron Therapeutics, based in Cary, North Carolina, and listed as HRTX, makes long-acting supportive care injectables: the antiemetics Sustol, an extended-release granisetron, and Cinvanti, an aprepitant emulsion, plus the post-surgical analgesic Zynrelef. Its polymer-based extended-release technology underlies Sustol, approved in 2016 for chemotherapy-induced nausea and vomiting, and Cinvanti, an intravenous aprepitant approved in 2017, while Aponvie and Zynrelef serve the surgical market. OnCo links it to the aprepitant and granisetron drug records. Whether long-acting formulations of generic antiemetics can command a premium is the commercial question its oncology products face. Granisetron and aprepitant have their own pages.
Headquarters
Cary, North Carolina, US
Scorecard
All companies#135of 1244 companies, score 42
- approved products +12
- modalities +2
- regions +2
- registry trials +26
2 approved, 0 in phase 3, 0 earlier, 0 targets, 175 registry studies. Formula on the scorecards page.
Type
Biotech · HRTX
Stage
Public
Website
Approved5-HT3 receptor antagonist (antiemetic)
Granisetron · Kytril (historic) / Sancuso / Sustol
Granisetron is an anti-sickness medicine for chemotherapy given as a tablet, an injection, a week-long skin patch (Sancuso) or a slow-release injection that lasts several days (Sustol).
ApprovedNeurokinin-1 receptor antagonist (antiemetic)
Aprepitant (and fosaprepitant) · Emend / Cinvanti
Aprepitant (Emend) was the first of a new class of anti-sickness drugs. Taken with a 5-HT3 blocker and dexamethasone, it prevents the delayed nausea and vomiting that follow strongly emetogenic chemotherapy such as cisplatin.
Similar pages
- TreatmentOndansetron
- TreatmentPalonosetron
- TechnologyAntiemetics for chemotherapy-induced nausea and vomiting
drugs
ApprovedNeurokinin-1 receptor antagonist (antiemetic)
Aprepitant (and fosaprepitant) · Emend / Cinvanti
Approved5-HT3 receptor antagonist (antiemetic)
Granisetron · Kytril (historic) / Sancuso / Sustol